Trial Profile
CAMPath and BELimumab for the Induction of Donor Specific Humoral Transplant Tolerance in Sensitized Kidney Transplant Recipients To Improve Long-Term Allograft Survival
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Jan 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Alemtuzumab; Mycophenolic acid; Steroids; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Acronyms CAMPBEL
- 06 Jan 2022 Status changed from recruiting to discontinued. Reason the study was stopped: Recruitment complications due to COVID-19
- 10 May 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Jun 2022.
- 10 Dec 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.